Genetic Evolution in BRCA1 ‐Associated Breast Cancer Reveals Early Driver Mutations Shaping Tumor Features and Prognosis
Cancer Science · 2026
DOI: 10.1111/cas.70460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Li Hu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hos…. Hauptthemen laut MEDLINE: BRCA1 Protein, Breast Neoplasms, Mutation, Evolution, Molecular. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Science Foundation of Peking University Cancer Hospital.
Abstract (Originalsprache)
Pathogenic germline variants in the BRCA1 gene significantly increase the lifetime risk of breast cancer and are frequently associated with early‐onset and triple‐negative disease. However, the chronology of genetic events during breast tumor evolution in BRCA1 carriers remains unclear. In this study, 57 primary breast tumors from 57 BRCA1 carriers were analyzed, including formalin‐fixed paraffin‐embedded specimens and fresh‐frozen specimens. Formalin‐fixed paraffin‐embedded tumors were microdissected into normal mammary tissue, carcinoma in situ, and invasive carcinoma components for deep target‐region sequencing, whereas fresh‐frozen tumors underwent whole‐exome sequencing and bulk transcriptome sequencing. Compared with non‐carriers from The Cancer Genome Atlas, breast cancers from BRCA1 carriers showed a distinct mutational landscape characterized by a high prevalence of TP53 mutations and a reduced frequency of PIK3CA and GATA3 alterations. Based on the initiating driver event, BRCA1 ‐associated tumors were classified into three subgroups: TP53 , PI(3)K‐AKT pathway, and unclassified. The TP53 ‐driven subgroup was strongly associated with the triple‐negative phenotype, loss of heterozygosity at the BRCA1 locus, and elevated genomic instability. TP53 truncating mutations were enriched in BRCA1 carriers compared with non‐carriers and showed a trend toward worse outcomes, potentially related to lower homologous recombination deficiency scores and activation of epithelial‐mesenchymal transition pathways. These findings highlight the distinct mutational architecture of breast cancers from BRCA1 carriers and suggest that TP53 truncating mutations may define a particularly aggressive subtype that warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, P. R. China.
- Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, P. R. China.
ORCID-Profile: Ye Xu, Yuntao Xie
Förderung
- National Natural Science Foundation of China
- Science Foundation of Peking University Cancer Hospital
Zitieren
APA
Hu, L., Li, Z., Wan, Q., Liao, X., Zhang, Y., Liu, Q., Ding, X., Meng, H., Wu, Y., Sun, J., Zhang, J., Yao, L., Xu, Y., & Xie, Y. (2026). Genetic Evolution in BRCA1 ‐Associated Breast Cancer Reveals Early Driver Mutations Shaping Tumor Features and Prognosis. Cancer Science. https://doi.org/10.1111/cas.70460
Vancouver
Hu L, Li Z, Wan Q, Liao X, Zhang Y, Liu Q, et al. Genetic Evolution in BRCA1 ‐Associated Breast Cancer Reveals Early Driver Mutations Shaping Tumor Features and Prognosis. Cancer Science. 2026. doi:10.1111/cas.70460
BibTeX
@article{Hu2026,
author = {Hu, Li and Li, Zhongwu and Wan, Qiting and Liao, Xingyu and Zhang, Yaxin and Liu, Qian and Ding, Xinyun and Meng, Hua and Wu, Yifan and Sun, Jie and Zhang, Juan and Yao, Lu and Xu, Ye and Xie, Yuntao},
title = {Genetic Evolution in BRCA1 ‐Associated Breast Cancer Reveals Early Driver Mutations Shaping Tumor Features and Prognosis},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70460}
}
EUVIMED